1 August 2018 - The second issue looks at today's listing of nivolumab (Opdivo) on the PBS for the treatment of patients with head and neck cancer.

Nivolumab can now be used by patients with squamous cell carcinoma of the head and neck that has progressed within 6 months following platinum-based therapy.

Nivolumab was listed on the PBS 390 days after its registration by the TGA.

Contact MAESTrO Database if you would like to receive a copy of the report.

Read MAESTrO Snapshot Report for nivolumab